| |
|
Registration Info | Hotel Info | Transportation | Visiting Tucson
Posters
ACoP will not be providing printed poster abstracts at the meeting. Individuals who desire a printed copy of the abstracts may download this PDF file (10.1MB) containing all poster abstracts in presentation order. Alternately, single poster PDF abstracts are available by clicking on a title below.
The following posters will be presented at ACoP during the morning and afternoon breaks. Posters numbered 1-20 will be presented by their authors on Monday morning, 21-39 Monday afternoon, 40-61 Tuesday morning, and 62-83 on Tuesday afternoon.
| order | Topic | Title | Abtract | Poster | Author(s) |
|---|---|---|---|---|---|
| 1 | Mechanistic Modeling/Systems Biology | Mechanism-based Models for Growth and Killing of Pseudomonas aeruginosa by Tobramycin to Quantify and Predict the Inoculum Effect | Jurgen B. Bulitta, Neang S. Ly, Brian T. Tsuji, William J. Jusko, Alan Forrest | ||
| 2 | Mechanistic Modeling/Systems Biology | Mechanistic Population Pharmacokinetics of Total and Unbound Paclitaxel for a New Nanodroplet Formulation vs. Taxol in Cancer Patients - A New Class of Models Based on Solubility Limited Drug Disposition | Jurgen B. Bulitta, Ping Zhao, Robert D. Arnold, Dean R. Kessler, Richard Daifuku, James Pratt, Gabriel Luciano, Axel-R Hanauske, Hans Gelderblom, Ahmad Awada, William J. Jusko | ||
| 3 | Mechanistic Modeling/Systems Biology | Population Modeling of Tumor Growth in a Murine Xenograft Model Following Administration of Biologic Drug Candidate | L. Zhao, G. Robbie, D. Jackson, J. Gooya, M. Camara, E. Gibiansky | ||
| 4 | Mechanistic Modeling/Systems Biology | Simultaneous Population Pharmacokinetic-Pharmacodynamic Modeling of Fospropofol Injection (Propofol Prodrug) and Propofol Emulsion in Healthy Volunteers | Leonid Gibiansky, Marc R. Gastonguay, Ajit Shah | ||
| 5 | Mechanistic Modeling/Systems Biology | Validation and Uncertainty Analysis of Physiologic Models | Richard Ho, Rebecca A. Baillie, Sam Holtzman | ||
| 6 | Mechanistic Modeling/Systems Biology | Predicting Affinity and Dose for an Antibody Inhibiting Target Dimerization | Helene Karcher, Matthias Machacek, Brian Stoll | ||
| 7 | Mechanistic Modeling/Systems Biology | Pharmacokinetic / Pharmacodynamic Modeling of Glucose Clamp Effects of Inhaled Insulin | Cornelia B. Landersdorfer, William J. Jusko | ||
| 8 | Mechanistic Modeling/Systems Biology | A Mechanism-based Population Model of Vildagliptin Pharmacokinetics and Dipeptidyl Peptidase IV Inhibition | - | Cornelia B. Landersdorfer, Yan-Ling He, Lise Kjems William J. Jusko | |
| 9 | Mechanistic Modeling/Systems Biology | Characterization of the Time-Varying Clearance of Rituximab in Nonhodgkin's Lymphoma Patients Using A Population Pharmacokinetic Analysis | PPT | Micha Levi, Jing Li, Nicolas Frey, Thian Kheoh, Song Ren, Michael Woo, Amita Joshi, Nancy Valente, Nelson 'Shasha' Jumbe, Jean-Eric Charoin | |
| 10 | Mechanistic Modeling/Systems Biology | Simulation of Midazolam Absorption and Bioavailability in Pediatric Patients | Viera Lukacova, Grazyna Fraczkiewicz, Walter S. Woltosz, Michael B. Bolger | ||
| 11 | Mechanistic Modeling/Systems Biology | Mechanism-based Population Pharmacokinetic Model of Oxaliplatin in Cancer Patients | - | Chee M Ng, Tim Synold, Chris Takimoto | |
| 12 | Mechanistic Modeling/Systems Biology | Mechanistic PBPK as an aid in identifying the size of covariate effects and design of POPPK studies: An example focusing on haematocrit as a determinant of tacrolimus clearance | PPT | Hisakazu Ohtani, Zoe Barter, Mohsen Aarabi, Tsuyoshi Minematsu, Masatoshi Makuuchi, Yasufumi Sawada, Geoffrey Tucker, Amin Rostami-Hodjegan | |
| 13 | Mechanistic Modeling/Systems Biology | Models of Asparaginase and Asparagine Pharmacokinetics and Pharmacodynamics in Pediatric Acute Lymphoblastic Leukemia | John C Panetta, Cheng Cheng, Wei Liu, Amar Gajjar, Nobuko Hijiya, Ching-Hon Pui, Mary V Relling | ||
| 14 | Mechanistic Modeling/Systems Biology | Mechanistic Models of Human Pharmacokinetics To Predict the Effects of Liver Cirrhosis on the Clearance of Nine Drugs | - | Trevor N Johnson, Koen Boussery, Sebastian Polak, Geoffrey T Tucker, Amin Rostami-Hodjegan | |
| 15 | Mechanistic Modeling/Systems Biology | An Extended Semi-Physiological Myelosuppression Model following Docetaxel administration with Improved Simulation Properties | Angelica L. Quartino, Lena E. Friberg, Mats O. Karlsson | ||
| 16 | Mechanistic Modeling/Systems Biology | Cross-Species Scaling of CNS Aß40 Response to a Gamma Secretase Inhibitor Through Semi-Mechanistic PK/PD Modeling and Application to Early Decision Making | Julie Stone, Laura Rosen, Jacquelynn Cook , Mark Shearman, Hong Sun, Michael Reilly, and Greg Winchell | ||
| 17 | Tools and Techniques | Constraining Methods In Estimating Three Compartment Pharmacokinetic Parameters | Jae Eun Ahn, Thomas Ludden | ||
| 18 | Tools and Techniques | Non-Linear Mixed Modeling of Serial Sacrifice Data: Potential Improvement in Estimation Using Information from Replicated Analytical Determinations | Kyle Baron and Richard Brundage | ||
| 19 | Tools and Techniques | Model-based tests of the effect of a genetic covariate on pharmacokinetic parameters using the SAEM algorithm | Julie Bertrand, Emmanuelle Comets, France Mentré | ||
| 20 | Tools and Techniques | A Simple Method for Approximating Population Pharmacokinetic Parameters | James Bosley | ||
| 21 | Tools and Techniques | Three-Stage Hierarchical Bayesian Analysis for Population Analysis of Complex PK/PD Models in S-ADAPT | Robert Bauer, Serge Guzy | ||
| 22 | Tools and Techniques | Comparison of Bias and Precision of Nonparametric and Parametric Population Methods assessed via Nonparametric Bootstrap Methods in NPAG and NONMEM | Jurgen B. Bulitta, Cornelia B. Landersdorfer, Alan Schumitzky, Michael Van Guilder, Roger W. Jelliffe | ||
| 23 | Tools and Techniques | Impact of Censoring Data Below an Arbitrary Quantification Limit on Structural Model Misspecification | PPT | Wonkyung Byon, Courtney V Fletcher, Richard C Brundage | |
| 24 | Tools and Techniques | Open Source Software Tools for Parallel Computation of Multiple MCMC Chains with WinBUGS | William R. Gillespie, Marc R. Gastonguay, William Knebel, George Georgalis | ||
| 25 | Tools and Techniques | Improving the Efficiency and Ensuring the Quality of Data Assembly for Pharmacometric Analysis | Thaddeus Grasela, Jill Fiedler-Kelly, Darcy Hitchcock | ||
| 26 | Tools and Techniques | Evaluation of an alternative approach for multiple-dose population pharmacokinetic data analysis in the presence of noncompliance | Pankaj Gupta, Matt Hutmacher, Bill Frame, Raymond Miller | ||
| 27 | Tools and Techniques | Automated Population Power Analysis Using The S-ADAPT MC-PEM Scripting Program: Application to Oncology Biotherapeutics | PPT | Serge Guzy , Robert Bauer | |
| 28 | Tools and Techniques | Large-scale simulations on a Linux cluster | David A. James, David Ohlssen | ||
| 29 | Tools and Techniques | Statistical Analysis of Methylene Chloride (dichloromethane, DCM) Closed Chamber Data Using Physiologically Based Pharmacokinetic Modeling | - | Martin Klein, Bimal Sinha | |
| 30 | Tools and Techniques | Facilitating the Pharmacometrics Work-Flow with the MItools R Package | William Knebel, Tim Bergsma, Jeannine Fisher, George Georgalis, Leonid Gibiansky, Bill Gillespie, Matt Riggs, Marc R. Gastonguay | ||
| 31 | Tools and Techniques | Effect of Miss-specified Covariance Structures on Estimated Fixed Effect Parameters from Non-Linear Mixed Effects Models for PK Data | Arun Krishna, Susan. A. Willavize | ||
| 32 | Tools and Techniques | Comparison of Nonparametric and Parametric Population Methods based on a Monte Carlo Simulation Study with Indirect Response Models I to IV in NPAG and NONMEM | Cornelia B. Landersdorfer, Jurgen B. Bulitta, Alan Schumitzky, Michael Van Guilder, Roger W. Jelliffe | ||
| 33 | Tools and Techniques | Normalised prediction distribution errors for the evaluation of nonlinear mixed-effects models: development of the npde add-on package for R | Emmanuelle Comets, Karl Brendel, France Mentré | ||
| 34 | Tools and Techniques | Dosing Strategies of Drugs with Narrow Therapeutic Windows: A simple Approach to Determine Trade-off Between Efficacy and Toxicity | Mohamad-Samer Mouksassi , Chunlin Chen , Jean-François Marier | ||
| 35 | Tools and Techniques | A Three-Stage Hierarchical Bayesian Mechanism-based Population Exposure/Interluekin-6 Response Model of Drug X in Patients with Immunological Disease | - | Chee M Ng, Amit Roy, Marc Pfister | |
| 36 | Tools and Techniques | Equivalent Constant Concentration Summarizes Pharmacokinetics in HIV and HCV PK/PD Modeling | Bill Poland | ||
| 37 | Tools and Techniques | Use Of Rpad, An Open-Source, Interactive, Web-Based Analysis Program, For Visualization During Model-Based Drug Development Of Adipiplon, A GABAA Receptor Partial Agonist Under Investigation For The Treatment Of Insomnia | Matthew M. Riggs, Timothy T. Bergsma, William R. Gillespie, Marc R. Gastonguay, Kenneth J. Sprenger | ||
| 38 | Tools and Techniques | Hierarchical Bayesian Exposure Response Analysis and Statistical Assessment of Heart Rate Corrected QT Interval (QTc) for Torcetrapib | Steven P Riley | ||
| 39 | Tools and Techniques | Comparison of the Performance of Likelihood-Based Methods Implemented in NONMEM and MCPEM/S-ADAPT to Account for Pharmacokinetic (PK) Data Below the Lower Limit of Quantification (LLOQ) | Scott Van Wart, Christopher Rubino, Alan Forrest, Olanrewaju Okusanya, Don Mager | ||
| 40 | Exposure-Response | Meta Analyses of Drug X using a Population Pharmacokinetic Approach | - | Jian Xu, Varun Goel, Varun Garg, Alaa Ahmad | |
| 41 | Exposure-Response | Population Pharmacokinetics and Exposure-Response Modeling and Simulation To Support Quinolone Phase IIA Dose Selection | PPT | Prachi Wickremasingha, Shashank Rohatagi, Christine Falcoz, Tatiana Khariton, Smita Kshirsagar, Helen Kastrissios, T.J. Carrothers, Jon Kuwabara-Wagg | |
| 42 | Exposure-Response | Model Based Dose Selection of a Quinolone To Minimize Drug Induced Serum Creatinine Elevation | PPT | Saeheum Song, Shashank Rohatagi, Prachi Wickremasingha, Tatiana Khariton, Smita Kshirsagar, T.J. Carrothers, Jon Kuwabara-Wagg | |
| 43 | Exposure-Response | Role of Modeling and Simulation in Evaluating the QTc Prolongation Potential of Drugs | PPT | Shashank Rohatagi, Saeheum Song, Tatiana Khariton, T.J. Carrothers, Jonathan Kuwabara-Wagg, Helen Kastrissios | |
| 44 | Exposure-Response | Model Based Development of a Direct Factor Xa Inhibitor | PPT | Shashank Rohatagi, Steve Haworth, Farkad Ezzet, Helen Katrissios, TJ Carrothers | |
| 45 | Exposure-Response | Qualification of an exposure-categorical ordered multi-response population model of inolimomab in graft-versus-host disease | PPT | Céline Dartois, Gilles Freyer, Mauricette Michallet, Emilie Hénin, Isabelle Darlavoix, Claudine Vermot-Desroches, Brigitte Tranchand, Pascal Girard | |
| 46 | Exposure-Response | Dose bridging in paediatric indications | Massimo Cella, Frederik Gorter de Vries, Meindert Danhof, Oscar Della Pasqua | ||
| 47 | Exposure-Response | Understanding the influence of obesity on the time course of pharmacological response | Phey Yen Han, Stephen B Duffull, Carl Kirkpatrick, Bruce Green | ||
| 48 | Exposure-Response | Population Pharmacokinetic Modeling of Fosamprenavir in Pediatric HIV-Infected Patients | Jeannine Fisher, Marc R. Gastonguay, William Knebel, Leonid Gibiansky, Mary Beth Wire | ||
| 49 | Exposure-Response | Lower Inter-occasion Variability than Inter-individual Variability in Chemotherapy-induced Myelosuppression | Lena E. Friberg, Emma Hansson, Johan Wallin, Mats O. Karlsson | ||
| 50 | Exposure-Response | Schedule Dependence in Tumor Response for 5-Fluorouracil in Colorectal Cancer | Lena E. Friberg, Mats O. Karlsson | ||
| 51 | Exposure-Response | Effects of Probenecid on the Pharmacokinetics of the Neuraminidase Inhibitor Oseltamivir | Ronald Gieschke, Craig Rayner, Lauren Boak, Pascal Chanu, Niclas Jonsson | ||
| 52 | Exposure-Response | The exposure-response driven development program, application to an anti-inflammatory compound | CJ Godfrey, Ene Ette | ||
| 53 | Exposure-Response | Exposure-Response Analysis for Spontaneously Reported Dizziness in Pregabalin Treated Patients with Generalized Anxiety Disorder | - | Kaori Ito, Matt Hutmacher, Jing Liu, Ruolun Qiu, Bill Frame, Raymond Miller | |
| 54 | Exposure-Response | Absorption Kinetics of Diazepam After Intranasal Administration | Vijay Ivaturi, Richard Brundage, James Cloyd | ||
| 55 | Exposure-Response | Model Qualification for Exposure Metrics: A Population Pharmacokinetic Example | PPT | Nitin Kaila, William F. Ebling, Jerry Nedelman, Ramesh Sarangapani | |
| 56 | Exposure-Response | Pharmacokinetics of Gemcitabine and Its Metabolites in Patients with Solid Tumors | Amit Khatri, Richard Brundage, Douglas Yee, Robert Kratzke, Mark Kirstein | ||
| 57 | Exposure-Response | Population pharmacokinetic analysis of perindoprilat in hypertensive paediatric patients | - | Céline M Laffont, France Mentré, Emmanuelle Foos-Gilbert | |
| 58 | Exposure-Response | Quantitative Methods for Impacting Resourcing and Design of Dose- and Dose Schedule-Finding Studies | PPT | Helen Moore, Cherry Lei, Shasha Jumbe | |
| 59 | Exposure-Response | Population Pharmacokinetic (PK) Pharmacodynamic (PD) Evaluation of Eritoran tetrasodium (E5564) in Patients with Severe Sepsis | Huachun Chen, Alec Wittek, Nancy Wong, Richard Kao, Melvyn Lynn, David J. Critchley, Diane R Mould | ||
| 60 | Exposure-Response | PK/PD Modeling of QTcF Duration for Vardenafil and Sildenafil Following Concomitant Administration with Gatifloxacin in Healthy Volunteers | Bela Patel, Duane Boyle, Marcella Paglione, Don Wallace, Bingming Yi, Thomas Hunt | ||
| 61 | Disease Progression | Optimizing trial designs for distinguishing short (symptomatic) and long-term (protective) treatment effects from natural disease progression | Bart Ploeger and Nick Holford | ||
| 62 | Exposure-Response | Pharmacodynamic Analysis of Hearing Impaired Neonates Treated with Amikacin | Catherine M.T. Sherwin, Sofia Svahn, Natalie J. Medlicott, Roland Broadbent, David M. Reith | ||
| 63 | Exposure-Response | Population PK/PD Modeling of Lumbar Spine Bone Mineral Density Response to 12 Months of Treatment with the Cathepsin K Inhibitor, Odanacatib, and Simulations to Further Evaluate the Dose-Response Relationship | Julie Stone, Stefan Zajic, Kevin Dykstra, Nidal Al-Huniti, Art Santora, Avery Ince, Bo Jin, Drew Denker | ||
| 64 | Exposure-Response | Model-based characterization of dose-response relationship in exploratory clinical development - extracting a small signal from noisy response data | PPT | Kai Wu, Michael Looby, Justin Wilkins, Per Olsson Gisleskog, Didier Renard, Marie-Odile Lemarechal, Steve Pascoe | |
| 65 | Exposure-Response | A Quantitative Look into the Effect of Glucose on Glucokinase Function in the Presence of an Activator | Michael Zager, Shaoxian Sun, Kathy Ogilvie | ||
| 66 | Exposure-Response | Modeling and Simulation to Quantify the Therapeutic Value of Drug X in A Combination Therapy | Min Zhu, Jianguo Li, Liang Zhao, Marc Pfister | ||
| 67 | Benefit-Risk Assessment/Decision Making | Linking Modeling & Simulation, Decision Analysis, and the Technology of Drug Formulation | PPT | Kevin Dykstra, Lee Hodge, T.J. Carrothers, Bob Korsan | |
| 68 | Benefit-Risk Assessment/Decision Making | Biomarker-based quantitative risk assessment for CYP3A induction DDI in early clinical development | Jonathan L. French, Karthik Venkatakrishnan | ||
| 69 | Benefit-Risk Assessment/Decision Making | An Improved Approach for Confirmatory Phase III Population Pharmacokinetics Analysis | Chuanpu Hu, Honghui Zhou | ||
| 70 | Benefit-Risk Assessment/Decision Making | Evaluation of a Drug Induced-QT/QTc Prolongation in the Presence of the Drug Induced Changes in Heart Rate by Using Population PK/PD Modeling Approach: Sibenadet Experience | Jianguo Li, Bruce Birmingham, Rogelio Mosqueda-Garcia, Nick Sander, Paul Newbold, Philip Sager | ||
| 71 | Benefit-Risk Assessment/Decision Making | Population Pharmacokinetic Models and Individualized Bayesian Dose Optimization in HIV Patients | PPT | Michael Neely, Roger Jelliffe | |
| 72 | Benefit-Risk Assessment/Decision Making | Evaluation of Warfarin Therapy Management Protocols via PK/PD Simulation | David H. Salinger, Paolo Vicini, Danny D. Shen, David L. Veenstra | ||
| 73 | Benefit-Risk Assessment/Decision Making | Quantitative "Learning" Analysis Supports Effectiveness of Heparin for STEMI | - | Hao Zhu, Norman Stockbridge, Yaning Wang, Joga Gobburu | |
| 74 | Exposure-Response | Leveraging Prior Quantitative Knowledge Demonstrates the Importance of Genotype-based Dosing of Warfarin | JY Lee, R Madabushi, LJ Lesko, SM Huang, D Schoenfeld, SZ Goldhaber, D Singer, MJ Kim, A Rahman, F Frueh, J Gobburu | ||
| 75 | Study Design/Conduct | Uncertainty and decision making in clinical development: the impact of an interim analysis based on the posterior predictive power on depression trials | Gijs Santen, Meindert Danhof, Oscar Della Pasqua | ||
| 76 | Study Design/Conduct | Applying Optimal Design Techniques to a Drug-Drug Interaction Study for a Triple Combination Therapy | PPT | James Dunyak, Nitin Kaila, Jerry Nedelman | |
| 77 | Study Design/Conduct | Evaluation of Phenytoin Bioavailability in Subjects on Maintenance Therapy Using a Stable-labeled Isotope Approach | Varun Goel, Richard C. Brundage, James C. Cloyd | ||
| 78 | Study Design/Conduct | Model-based and trial simulation approach to estimate antidepressant drug effect in multi-center clinical trials: relevance of placebo response in the different recruitment centers | - | Roberto Gomeni | |
| 79 | Study Design/Conduct | An extension of PFIM for optimal population design in multiple response nonlinear mixed effects models: PFIM 3.0 | C. Bazzoli, S. Retout, F. Mentré | ||
| 80 | Study Design/Conduct | A Statistical Software Approach to Bayesian Response-Adaptive Design for Dose Finding | Michael O'Connell, Dawn Woodard | ||
| 81 | Study Design/Conduct | Optimizing Sampling Designs for Apixaban Phase III Studies using Trial Simulation | Tarek A. Leil, Anne Paccaly, Marc Pfister | ||
| 82 | Study Design/Conduct | Assessment of probability of success for the outcome of a noninferiority trial comparing two bioinequivalent, fixed-dose combination drugs | William M. Sallas, Joseph Kahn, Steven Kern | ||
| 83 | Study Design/Conduct | Optimal design of the intravenous glucose tolerance test in type 2 diabetic patients | PPT | Hanna E Silber, Joakim Nyberg, Andrew Hooker, Mats O Karlsson | |
| 84 | Study Design/Conduct | Targeted Phase I Oncology Trial | Yen Lin Chia, Jerry Nedelman, Roland Fisch, Brian Stoll, William Sellers |